AFM13 in Relapsed/Refractory Cutaneous Lymphomas
NCT03192202
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma, T-Cell, Cutaneous
Interventions
DRUG:
AFM13
Sponsor
Ahmed Sawas